Expand APGE Menu
APGE MENU

APGE Latest Press Releases

-- February 16, 2026 --

Atopic Dermatitis Market to Accelerate at a Rapid Pace by 2034 with Advancements in Biologics and JAK Inhibitors | DelveInsight PRNewswire 5:31 PM

-- February 5, 2026 --

Apogee Therapeutics to Participate at the Guggenheim Emerging Outlook: Biotech Summit 2026 Globe Newswire 8:00 AM

-- January 6, 2026 --

Apogee Therapeutics Announces Positive Interim Results from Phase 1b Trial of Zumilokibart (APG777), its Potentially Best-in-Class Anti-IL-13 Antibody, in Patients with Mild-to-Moderate Asthma and Highlights 2026 Anticipated Milestones and Outlook Globe Newswire 6:00 AM

-- January 5, 2026 --

Apogee Therapeutics to Host Conference Call to Report Interim Results from the Phase 1b Trial of APG777 in Patients with Mild-to-Moderate Asthma and 2026 Anticipated Milestones on January 6, 2026 Globe Newswire 4:01 PM

-- November 10, 2025 --

Apogee Therapeutics Provides Pipeline Progress and Reports Third Quarter 2025 Financial Results Globe Newswire 7:10 AM
Apogee Therapeutics Announces Positive Interim Phase 1 Results from Healthy Volunteer Trial of APG333, its Novel Half-Life Extended TSLP Antibody Globe Newswire 7:00 AM

-- November 3, 2025 --

Apogee Therapeutics to Participate in Upcoming Conferences Globe Newswire 7:30 AM

-- October 10, 2025 --

Apogee Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares for Gross Proceeds of $345 Million Globe Newswire 4:01 PM

-- October 8, 2025 --

Apogee Therapeutics, Inc. Announces Pricing of $300 Million Underwritten Public Offering Globe Newswire 9:52 PM
Apogee Therapeutics, Inc. Announces Proposed Underwritten Public Offering Globe Newswire 4:01 PM
Market Data Delayed 15 Minutes